Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time:A meta-analysis of 60 randomized controlled trials

Title: Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time:A meta-analysis of 60 randomized controlled trials
Authors: Burger, Pascal M.; Dorresteijn, Jannick A.N.; Koudstaal, Stefan; Holtrop, Joris; Kastelein,John J.P.; Jukema,J. Wouter; Ridker,Paul M.; Mosterd, Arend; Visseren, Frank L.J.; Interne Geneeskunde Vasculaire; MS Vasculaire & Endocrinologie; Circulatory Health
Publication Year: 2024
Subject Terms: Cardiology and Cardiovascular Medicine
Description: Background and aims: Individuals with or at high risk of cardiovascular disease (CVD) often receive long-term treatment with low-density lipoprotein cholesterol (LDL-C) lowering therapies, but whether the effects of LDL-C reduction remain stable over time is uncertain. This study aimed to establish the course of the effects of LDL-C reduction on cardiovascular risk over time. Methods: Randomized controlled trials (RCTs) of LDL-C lowering therapies were identified through a search in MEDLINE and EMBASE (1966–January 2023). The primary analyses were restricted to statins, ezetimibe, and proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors, with other therapies included in sensitivity analyses. Random-effects meta-analyses were performed to establish the hazard ratio (HR) for major vascular events (cardiovascular death, myocardial infarction, unstable angina, coronary revascularization, or stroke) per 1 mmol/L LDL-C reduction. Course of the effects over time was assessed using random-effects meta-regression analyses for the association between follow-up duration, age, and the HR for major vascular events per 1 mmol/L LDL-C reduction. Additionally, treatment-by-time interactions were evaluated in an individual participant data meta-analysis of six atorvastatin trials. Results: A total of 60 RCTs were identified (408,959 participants, 51,425 major vascular events). The HR for major vascular events per 1 mmol/L LDL-C reduction was 0.78 (95 % confidence interval [CI] 0.75–0.81). Follow-up duration was not associated with a change in the HR for major vascular events (HR for change per year 0.994; 95 % CI 0.970–1.020; p = 0.66). The HR attenuated with increasing age in primary prevention (HR for change per 5 years 1.097; 95 % CI 1.031–1.168; p = 0.003), but not secondary prevention (HR for change per 5 years 0.987; 95 % CI 0.936–1.040; p = 0.63). Consistent results were found for statin trials only, and all trials combined. In the individual participant data meta-analysis (31,310 participants, 6734 major ...
Document Type: article in journal/newspaper
File Description: text/plain
Language: English
ISSN: 0021-9150
Relation: https://dspace.library.uu.nl/handle/1874/455086
Availability: https://dspace.library.uu.nl/handle/1874/455086
Rights: info:eu-repo/semantics/OpenAccess
Accession Number: edsbas.E7CD3C1D
Database: BASE